Ivermectol is a broad-spectrum antiparasitic agent belonging to the avermectin class, indicated for the treatment of a range of parasitic infections caused by nematodes and ectoparasites. Its mechanism of action involves high-affinity binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased cell permeability to chloride ions, hyperpolarization, and subsequent paralysis and death of the parasite. It exhibits a strong safety profile in mammals due to the relative scarcity of these target channels and the protective nature of the blood-brain barrier. This product is available in oral tablet formulation, designed for systemic distribution to target both tissue-dwelling and blood-feeding parasites effectively.

Features

• Active ingredient: Ivermectin 3mg or 6mg tablets
• Pharmacological class: Avermectin anthelmintic
• Mechanism: Agonist of glutamate-gated chloride channels
• High bioavailability when administered orally
• Extensive tissue distribution with limited CNS penetration
• Metabolized primarily in the liver via CYP450 enzymes
• Excretion predominantly fecal, with minor renal clearance

Benefits

• Effectively eliminates a broad spectrum of nematode parasites
• Reduces transmission of parasitic diseases in endemic areas
• Single-dose regimen for many indications improves compliance
• Demonstrates ovicidal activity against certain parasite species
• Low incidence of severe adverse reactions at therapeutic doses
• Contributes to mass drug administration programs for disease control

Common use

Ivermectol is primarily indicated for the treatment of onchocerciasis (river blindness), strongyloidiasis of the intestinal tract, and scabies infestations. It is also used off-label for the management of other parasitic infections, including cutaneous larva migrans, ascariasis, trichuriasis, and enterobiasis. In veterinary medicine, it is employed against a wider range of ecto- and endoparasites. Public health programs utilize Ivermectol in mass drug administration campaigns to reduce the prevalence of lymphatic filariasis in combination with other agents.

Dosage and direction

Dosing is weight-based and indication-specific. For onchocerciasis: a single oral dose of 150 mcg/kg. For strongyloidiasis: a single oral dose of 200 mcg/kg. Tablets should be taken on an empty stomach with water. Dosing may be repeated every 3–12 months for certain conditions based on parasitic life cycles and reinfection risk. Specific populations (pediatric, hepatic impairment) require dosage adjustment. Always follow prescribing physician instructions.

Precautions

Use with caution in patients with hepatic impairment due to extensive metabolism. Not recommended during pregnancy unless potential benefit justifies potential risk. Breastfeeding should be interrupted for several days post-dose due to secretion in milk. Loa loa coinfection requires special consideration due to risk of serious encephalopathic reactions. Patients should avoid driving or operating machinery if experiencing dizziness.

Contraindications

Hypersensitivity to ivermectin or any component of the formulation. Concomitant use with other agents that increase blood-brain barrier permeability (e.g., certain immunosuppressants). Patients with loiasis and high microfilarial loads due to risk of severe encephalopathy. Meningitis or other CNS conditions that may compromise blood-brain barrier integrity.

Possible side effect

Common: dizziness, pruritus, fever, rash, myalgia, arthralgia, diarrhea, orthostatic hypotension. Less common: eosinophilia, elevated liver enzymes, tachycardia. Rare: severe skin reactions, hypotension, leukopenia. Very rare: encephalopathy (particularly in loiasis coinfection), hepatitis.

Drug interaction

Potentiated effects with other P-glycoprotein substrates. CYP3A4 inhibitors (e.g., ketoconazole) may increase ivermectin concentrations. Warfarin may require monitoring due to potential protein binding displacement. Barbiturates, benzodiazepines, and valproic acid may have enhanced CNS effects. Use caution with other antiparasitic agents that may increase neurological adverse effects.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose. For single-dose regimens, administer as soon as possible and resume normal schedule. Consult healthcare provider if uncertainty exists regarding timing.

Overdose

Symptoms may include exaggerated pharmacological effects: severe nausea, vomiting, diarrhea, dizziness, hypotension, respiratory depression, and CNS effects including confusion, coma, or death in extreme cases. Treatment is supportive: gastric lavage if recent ingestion, activated charcoal, and symptomatic management. No specific antidote exists. Dialysis is not effective due to high protein binding.

Storage

Store at controlled room temperature (15–30°C) in original container. Protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date. Do not transfer to other containers as humidity may degrade the product.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Diagnosis and treatment should be determined by a qualified healthcare provider. Off-label use should be undertaken only under medical supervision. Manufacturer is not liable for misuse or incorrect application.

Reviews

“Clinical efficacy in our strongyloidiasis cohort was exceptional, with 95% clearance rates at 4-week follow-up.” – Journal of Clinical Parasitology

“Mass administration programs using Ivermectol have significantly reduced onchocerciasis transmission in endemic regions.” – World Health Organization Bulletin

“Neurological adverse events are rare but require vigilance, particularly in areas endemic for Loa loa.” – Tropical Medicine and International Health

“Single-dose convenience dramatically improves compliance in public health initiatives compared to multi-day regimens.” – Global Health Action